XML 57 R39.htm IDEA: XBRL DOCUMENT
v3.25.1

Net Loss Per Share (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Earnings Per Share [Abstract] |
Schedule of Net Loss Per Share Basic and Diluted | The Net loss per share basic and diluted for the respective periods indicated is as follows: Schedule of Net Loss Per Share Basic and Diluted
|  | 2024 |  |  | 2023 |
|  | Years Ended December 31, |
|  | 2024 |  |  | 2023 |
Numerator |  |  |  |  |  |  |  |
Net loss |  | $ | (45,529 | ) |  | $ | (52,666 | )
Deemed dividend on Series A and Series A-1 Convertible Preferred Stock |  |  | (7,496 | ) |  |  | — |
Net loss attributable to Lucid Diagnostics Inc. common stockholders |  | $ | (53,025 | ) |  | $ | (52,666 | )
Denominator |  |  |  |  |  |  |  |
Weighted average common shares outstanding, basic and diluted |  |  | 50,515,773 |  |  |  | 41,756,129 |
Net loss per share (1) |  |  |  |  |  |  |  |
Net loss per share - basic and diluted |  | $ | (1.05 | ) |  | $ | (1.26 | )
(1) | - Convertible Preferred Stock would potentially be considered a participating security under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and as such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net loss per share calculation for the periods indicated.
Schedule of Common Stock Equivalents Excluded from Computation of Diluted Earnings Per Share | Schedule of Common Stock Equivalents Excluded from Computation of Diluted Earnings Per Share
|  | 2024 |  |  | 2023 |
|  | December 31, |
|  | 2024 |  |  | 2023 |
Stock options |  |  | 8,646,758 |  |  |  | 5,504,383 |
Unvested restricted stock awards |  |  | 3,897,440 |  |  |  | 2,337,440 |
Preferred stock |  |  | 49,607,115 |  |  |  | 13,744,812 |
Total |  |  | 62,151,313 |  |  |  | 21,586,635 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration